GlassScriptPhysician profile
Rehan Shamim
NPI 1730314485
$6,549.02
in general payments reported to CMS, 2019-2025
34 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $978 · 2021: $820 · 2022: $2,094 · 2023: $1,908 · 2024: $330 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,365 · Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,365.00 |
| Food and Beverage | $982.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $1,792.50 | 2022-2023 | |
| Ethicon INC. | $675.00 | 2020 | |
| Zimmer Biomet Holdings, INC. | $587.83 | 2021-2024 | Tapestry, Stratum Foot Plating System |
| Medtronic, INC. | $577.98 | 2022-2023 | Mazor X System |
| Stryker Corporation | $453.54 | 2020-2024 | Gamma, Axsos |
| Zoll Medical Corporation | $450.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $435.00 | 2021 | |
| Seapearl East, INC | $338.27 | 2022-2023 | |
| Bioventus LLC | $208.35 | 2019-2022 | |
| Depuy Synthes Sales INC. | $153.84 | 2021-2025 | Microfix Quickanchor Ethibond, Quickanchor Ethibond, Dynacord |
| Abbvie INC. | $123.43 | 2023 | Botox |
| Sanofi-Aventis U.S. LLC | $71.40 | 2019-2021 | |
| Horizon Therapeutics Plc | $61.77 | 2019-2022 | |
| Heron Therapeutics, INC. | $61.25 | 2022-2024 | Zynrelef |
| Pacira Pharmaceuticals Incorporated | $60.34 | 2021-2024 | Iovera, Zilretta, Exparel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $57.48 | 2022-2023 | Seglentis |
| Boston Scientific Corporation | $45.04 | 2021 | |
| Globus Medical, INC. | $40.26 | 2025 | Anthem |
| Orthosensor INC. | $40.00 | 2020 | |
| Integra Lifesciences Corporation | $33.39 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Heraeus Medical, LLC. | $31.60 | 2022 | |
| Endo Pharmaceuticals INC. | $29.35 | 2019 | |
| Intellijoint Surgical INC. | $29.25 | 2020 | |
| Misonix INC | $25.53 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.33 | 2019 | |
| Convatec INC. | $22.59 | 2023 | |
| Abbott Laboratories | $19.12 | 2021 | |
| Fidia Pharma USA INC. | $18.67 | 2019 | |
| Hologic Sales and Service, LLC | $14.59 | 2019 | |
| Pacira Therapeutics, INC. | $14.07 | 2021 | |
| Zyla Life Sciences, INC. | $13.77 | 2019 | |
| Smith+Nephew, INC. | $13.70 | 2020 | |
| Hikma Pharmaceuticals USA | $13.39 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Shamim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.